Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro
Authors:
- Bernd-Uwe SevinBSBernd-Uwe Sevin
- James P. PerrasJPJames P. Perras
- Roberto AngioliRARoberto Angioli
- Andrea BaiblABAndrea Baibl
- Hoa N. NguyenHNHoa N. Nguyen
- Randy D. HightowerRHRandy D. Hightower
- Hervy E. AveretteHAHervy E. Averette
Open Access
- 1 November 1992
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 47 (2) , 172-178
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Comparative evaluation of pirarubicin and adriamycin in gynecologic cancer cell linesGynecologic Oncology, 1992
- Comparative evaluation of single and combination chemotherapy in uterine cancer cell linesGynecologic Oncology, 1991
- A phase II study of pirarubicin in malignant pleural mesotheliomaCancer, 1990
- Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescenceGynecologic Oncology, 1990
- Application of an ATP-bioluminescence assay in human tumor chemosensitivity testingGynecologic Oncology, 1988
- A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinomaGynecologic Oncology, 1987
- Treatment of acute leukemia and malignant lymphoma with (2?R)-4?-O-tetrahydropyranyladriamycinCancer Chemotherapy and Pharmacology, 1987
- RadiotherapyNew England Journal of Medicine, 1983
- Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinomaGynecologic Oncology, 1982
- Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycinCancer, 1981